1
|
Jaiswal S, Singh B, Dhingra I, Joshi A, Kodgire P. Bioremediation and bioscavenging for elimination of organophosphorus threats: An approach using enzymatic advancements. ENVIRONMENTAL RESEARCH 2024; 252:118888. [PMID: 38599448 DOI: 10.1016/j.envres.2024.118888] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/24/2023] [Revised: 02/06/2024] [Accepted: 04/05/2024] [Indexed: 04/12/2024]
Abstract
Organophosphorus compounds (OP) are highly toxic pesticides and nerve agents widely used in agriculture and chemical warfare. The extensive use of these chemicals has severe environmental implications, such as contamination of soil, water bodies, and food chains, thus endangering ecosystems and biodiversity. Plants absorb pesticide residues, which then enter the food chain and accumulate in the body fat of both humans and animals. Numerous human cases of OP poisoning have been linked to both acute and long-term exposure to these toxic OP compounds. These compounds inhibit the action of the acetylcholinesterase enzyme (AChE) by phosphorylation, which prevents the breakdown of acetylcholine (ACh) neurotransmitter into choline and acetate. Thus, it becomes vital to cleanse the environment from these chemicals utilizing various physical, chemical, and biological methods. Biological methods encompassing bioremediation using immobilized microbes and enzymes have emerged as environment-friendly and cost-effective approaches for pesticide removal. Cell/enzyme immobilized systems offer higher stability, reusability, and ease of product recovery, making them ideal tools for OP bioremediation. Interestingly, enzymatic bioscavengers (stoichiometric, pseudo-catalytic, and catalytic) play a vital role in detoxifying pesticides from the human body. Catalytic bioscavenging enzymes such as Organophosphate Hydrolase, Organophosphorus acid anhydrolase, and Paraoxonase 1 show high degradation efficiency within the animal body as well as in the environment. Moreover, these enzymes can also be employed to decontaminate pesticides from food, ensuring food safety and thus minimizing human exposure. This review aims to provide insights to potential collaborators in research organizations, government bodies, and industries to bring advancements in the field of bioremediation and bioscavenging technologies for the mitigation of OP-induced health hazards.
Collapse
Affiliation(s)
- Surbhi Jaiswal
- Department of Biosciences and Biomedical Engineering, Indian Institute of Technology, Indore, Simrol, Khandwa Road, Indore, 453552, India
| | - Brijeshwar Singh
- Department of Biosciences and Biomedical Engineering, Indian Institute of Technology, Indore, Simrol, Khandwa Road, Indore, 453552, India
| | - Isha Dhingra
- Department of Biosciences and Biomedical Engineering, Indian Institute of Technology, Indore, Simrol, Khandwa Road, Indore, 453552, India
| | - Abhijeet Joshi
- Department of Biosciences and Biomedical Engineering, Indian Institute of Technology, Indore, Simrol, Khandwa Road, Indore, 453552, India.
| | - Prashant Kodgire
- Department of Biosciences and Biomedical Engineering, Indian Institute of Technology, Indore, Simrol, Khandwa Road, Indore, 453552, India.
| |
Collapse
|
2
|
Zou S, Wang Q, He Q, Liu G, Song J, Li J, Wang F, Huang Y, Hu Y, Zhou D, Lv Y, Zhu Y, Wang B, Zhang L. Brain-targeted nanoreactors prevent the development of organophosphate-induced delayed neurological damage. J Nanobiotechnology 2023; 21:256. [PMID: 37550745 PMCID: PMC10405429 DOI: 10.1186/s12951-023-02039-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2023] [Accepted: 07/31/2023] [Indexed: 08/09/2023] Open
Abstract
BACKGROUND Organophosphate (OP)-induced delayed neurological damage is attributed to permanent neuropathological lesions caused by irreversible OP-neurocyte interactions, without potent brain-targeted etiological antidotes to date. The development of alternative therapies to achieve intracerebral OP detoxification is urgently needed. METHODS We designed a brain-targeted nanoreactor by integrating enzyme immobilization and biomimetic membrane camouflaging protocols with careful characterization, and then examined its blood-brain barrier (BBB) permeability both in vitro and in vivo. Subsequently, the oxidative stress parameters, neuroinflammatory factors, apoptotic proteins and histopathological changes were measured and neurobehavioral tests were performed. RESULTS The well-characterized nanoreactors exerted favourable BBB penetration capability both in vitro and in vivo, significantly inhibiting OP-induced intracerebral damage. At the cellular and tissue levels, nanoreactors obviously blocked oxidative stress, cellular apoptosis, inflammatory reactions and brain histopathological damage. Furthermore, nanoreactors radically prevented the occurrence of OP-induced delayed cognitive deficits and psychiatric abnormality. CONCLUSION The nanoreactors significantly prevented the development of OP-induced delayed neurological damage, suggesting a potential brain-targeted etiological strategy to attenuate OP-related delayed neurological and neurobehavioral disorders.
Collapse
Affiliation(s)
- Shuaijun Zou
- Department of Marine Biomedicine and Polar Medicine, Naval Special Medical Centre, Naval Medical University, Shanghai, 200433, China
| | - Qianqian Wang
- Department of Marine Biomedicine and Polar Medicine, Naval Special Medical Centre, Naval Medical University, Shanghai, 200433, China
| | - Qian He
- The Third Affiliated Hospital, Naval Medical University, Shanghai, 200433, China
| | - Guoyan Liu
- Department of Marine Biomedicine and Polar Medicine, Naval Special Medical Centre, Naval Medical University, Shanghai, 200433, China
| | - Juxingsi Song
- Department of Marine Biomedicine and Polar Medicine, Naval Special Medical Centre, Naval Medical University, Shanghai, 200433, China
| | - Jie Li
- Department of Marine Biomedicine and Polar Medicine, Naval Special Medical Centre, Naval Medical University, Shanghai, 200433, China
| | - Fan Wang
- Department of Marine Biomedicine and Polar Medicine, Naval Special Medical Centre, Naval Medical University, Shanghai, 200433, China
| | - Yichao Huang
- Department of Marine Biomedicine and Polar Medicine, Naval Special Medical Centre, Naval Medical University, Shanghai, 200433, China
| | - Yanan Hu
- Department of Marine Biomedicine and Polar Medicine, Naval Special Medical Centre, Naval Medical University, Shanghai, 200433, China
| | - Dayuan Zhou
- Department of Marine Biomedicine and Polar Medicine, Naval Special Medical Centre, Naval Medical University, Shanghai, 200433, China
| | - Yongfei Lv
- Department of Marine Biomedicine and Polar Medicine, Naval Special Medical Centre, Naval Medical University, Shanghai, 200433, China
| | - Yuanjie Zhu
- Department of Marine Biological Injury and Dermatology, Naval Special Medical Centre, Naval Medical University, Shanghai, 200052, China.
| | - Beilei Wang
- Department of Marine Biomedicine and Polar Medicine, Naval Special Medical Centre, Naval Medical University, Shanghai, 200433, China.
| | - Liming Zhang
- Department of Marine Biomedicine and Polar Medicine, Naval Special Medical Centre, Naval Medical University, Shanghai, 200433, China.
| |
Collapse
|
3
|
Kon E, Levy Y, Elia U, Cohen H, Hazan-Halevy I, Aftalion M, Ezra A, Bar-Haim E, Naidu GS, Diesendruck Y, Rotem S, Ad-El N, Goldsmith M, Mamroud E, Peer D, Cohen O. A single-dose F1-based mRNA-LNP vaccine provides protection against the lethal plague bacterium. SCIENCE ADVANCES 2023; 9:eadg1036. [PMID: 36888708 PMCID: PMC9995031 DOI: 10.1126/sciadv.adg1036] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/02/2022] [Accepted: 02/08/2023] [Indexed: 05/28/2023]
Abstract
Messenger RNA (mRNA) lipid nanoparticle (LNP) vaccines have emerged as an effective vaccination strategy. Although currently applied toward viral pathogens, data concerning the platform's effectiveness against bacterial pathogens are limited. Here, we developed an effective mRNA-LNP vaccine against a lethal bacterial pathogen by optimizing mRNA payload guanine and cytosine content and antigen design. We designed a nucleoside-modified mRNA-LNP vaccine based on the bacterial F1 capsule antigen, a major protective component of Yersinia pestis, the etiological agent of plague. Plague is a rapidly deteriorating contagious disease that has killed millions of people during the history of humankind. Now, the disease is treated effectively with antibiotics; however, in the case of a multiple-antibiotic-resistant strain outbreak, alternative countermeasures are required. Our mRNA-LNP vaccine elicited humoral and cellular immunological responses in C57BL/6 mice and conferred rapid, full protection against lethal Y. pestis infection after a single dose. These data open avenues for urgently needed effective antibacterial vaccines.
Collapse
Affiliation(s)
- Edo Kon
- Laboratory of Precision NanoMedicine, Shmunis School for Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel
- Center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv 69978, Israel
- Department of Materials Sciences and Engineering, Iby and Aladar Fleischman Faculty of Engineering, Tel Aviv University, Tel Aviv 69978, Israel
- Cancer Biology Research Center, Tel Aviv University, Tel Aviv 69978, Israel
| | - Yinon Levy
- Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 76100, Israel
| | - Uri Elia
- Laboratory of Precision NanoMedicine, Shmunis School for Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel
- Center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv 69978, Israel
- Department of Materials Sciences and Engineering, Iby and Aladar Fleischman Faculty of Engineering, Tel Aviv University, Tel Aviv 69978, Israel
- Cancer Biology Research Center, Tel Aviv University, Tel Aviv 69978, Israel
- Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 76100, Israel
| | - Hila Cohen
- Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 76100, Israel
| | - Inbal Hazan-Halevy
- Laboratory of Precision NanoMedicine, Shmunis School for Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel
- Center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv 69978, Israel
- Department of Materials Sciences and Engineering, Iby and Aladar Fleischman Faculty of Engineering, Tel Aviv University, Tel Aviv 69978, Israel
- Cancer Biology Research Center, Tel Aviv University, Tel Aviv 69978, Israel
| | - Moshe Aftalion
- Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 76100, Israel
| | - Assaf Ezra
- Laboratory of Precision NanoMedicine, Shmunis School for Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel
- Center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv 69978, Israel
- Department of Materials Sciences and Engineering, Iby and Aladar Fleischman Faculty of Engineering, Tel Aviv University, Tel Aviv 69978, Israel
- Cancer Biology Research Center, Tel Aviv University, Tel Aviv 69978, Israel
| | - Erez Bar-Haim
- Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 76100, Israel
| | - Gonna Somu Naidu
- Laboratory of Precision NanoMedicine, Shmunis School for Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel
- Center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv 69978, Israel
- Department of Materials Sciences and Engineering, Iby and Aladar Fleischman Faculty of Engineering, Tel Aviv University, Tel Aviv 69978, Israel
- Cancer Biology Research Center, Tel Aviv University, Tel Aviv 69978, Israel
| | - Yael Diesendruck
- Laboratory of Precision NanoMedicine, Shmunis School for Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel
- Center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv 69978, Israel
- Department of Materials Sciences and Engineering, Iby and Aladar Fleischman Faculty of Engineering, Tel Aviv University, Tel Aviv 69978, Israel
- Cancer Biology Research Center, Tel Aviv University, Tel Aviv 69978, Israel
| | - Shahar Rotem
- Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 76100, Israel
| | - Nitay Ad-El
- Laboratory of Precision NanoMedicine, Shmunis School for Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel
- Center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv 69978, Israel
- Department of Materials Sciences and Engineering, Iby and Aladar Fleischman Faculty of Engineering, Tel Aviv University, Tel Aviv 69978, Israel
- Cancer Biology Research Center, Tel Aviv University, Tel Aviv 69978, Israel
| | - Meir Goldsmith
- Laboratory of Precision NanoMedicine, Shmunis School for Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel
- Center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv 69978, Israel
- Department of Materials Sciences and Engineering, Iby and Aladar Fleischman Faculty of Engineering, Tel Aviv University, Tel Aviv 69978, Israel
- Cancer Biology Research Center, Tel Aviv University, Tel Aviv 69978, Israel
| | - Emanuelle Mamroud
- Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 76100, Israel
| | - Dan Peer
- Laboratory of Precision NanoMedicine, Shmunis School for Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel
- Center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv 69978, Israel
- Department of Materials Sciences and Engineering, Iby and Aladar Fleischman Faculty of Engineering, Tel Aviv University, Tel Aviv 69978, Israel
- Cancer Biology Research Center, Tel Aviv University, Tel Aviv 69978, Israel
| | - Ofer Cohen
- Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 76100, Israel
| |
Collapse
|
4
|
Falach R, Bar-On L, Lazar S, Kadar T, Mazor O, Aftalion M, Gur D, Evgy Y, Shifman O, Aminov T, Israeli O, Cohen-Gihon I, Zaide G, Gutman H, Vagima Y, Makdasi E, Stein D, Rosenfeld R, Alcalay R, Zahavy E, Levy H, Glinert I, Ben-Shmuel A, Israely T, Melamed S, Politi B, Achdout H, Yitzhaki S, Kronman C, Sabo T. Mice with induced pulmonary morbidities display severe lung inflammation and mortality following exposure to SARS-CoV-2. JCI Insight 2021; 6:145916. [PMID: 33974566 PMCID: PMC8262502 DOI: 10.1172/jci.insight.145916] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2020] [Accepted: 05/06/2021] [Indexed: 01/04/2023] Open
Abstract
Mice are normally unaffected by SARS coronavirus 2 (SARS-CoV-2) infection since the virus does not bind effectively to the murine version of the angiotensin-converting enzyme 2 (ACE2) receptor molecule. Here, we report that induced mild pulmonary morbidities rendered SARS-CoV-2–refractive CD-1 mice susceptible to this virus. Specifically, SARS-CoV-2 infection after application of low doses of the acute lung injury stimulants bleomycin or ricin caused severe disease in CD-1 mice, manifested by sustained body weight loss and mortality rates greater than 50%. Further studies revealed markedly higher levels of viral RNA in the lungs, heart, and serum of low-dose ricin–pretreated mice compared with non-pretreated mice. Furthermore, lung extracts prepared 2–3 days after viral infection contained subgenomic mRNA and virus particles capable of replication only when derived from the pretreated mice. The deleterious effects of SARS-CoV-2 infection were effectively alleviated by passive transfer of polyclonal or monoclonal antibodies generated against the SARS-CoV-2 receptor binding domain (RBD). Thus, viral cell entry in the sensitized mice seems to depend on viral RBD binding, albeit by a mechanism other than the canonical ACE2-mediated uptake route. This unique mode of viral entry, observed over a mildly injured tissue background, may contribute to the exacerbation of coronavirus disease 2019 (COVID-19) pathologies in patients with preexisting morbidities.
Collapse
Affiliation(s)
- Reut Falach
- Department of Biochemistry and Molecular Genetics
| | - Liat Bar-On
- Department of Biochemistry and Molecular Genetics
| | | | | | - Ohad Mazor
- Department of Infectious Diseases, Israel Institute for Biological Research, Ness-Ziona, Israel
| | | | - David Gur
- Department of Biochemistry and Molecular Genetics
| | - Yentl Evgy
- Department of Biochemistry and Molecular Genetics
| | - Ohad Shifman
- Department of Biochemistry and Molecular Genetics
| | - Tamar Aminov
- Department of Biochemistry and Molecular Genetics
| | - Ofir Israeli
- Department of Biochemistry and Molecular Genetics
| | | | - Galia Zaide
- Department of Biochemistry and Molecular Genetics
| | | | - Yaron Vagima
- Department of Biochemistry and Molecular Genetics
| | - Efi Makdasi
- Department of Infectious Diseases, Israel Institute for Biological Research, Ness-Ziona, Israel
| | - Dana Stein
- Department of Biochemistry and Molecular Genetics
| | | | - Ron Alcalay
- Department of Biochemistry and Molecular Genetics
| | - Eran Zahavy
- Department of Biochemistry and Molecular Genetics
| | - Haim Levy
- Department of Infectious Diseases, Israel Institute for Biological Research, Ness-Ziona, Israel
| | - Itai Glinert
- Department of Infectious Diseases, Israel Institute for Biological Research, Ness-Ziona, Israel
| | - Amir Ben-Shmuel
- Department of Infectious Diseases, Israel Institute for Biological Research, Ness-Ziona, Israel
| | - Tomer Israely
- Department of Infectious Diseases, Israel Institute for Biological Research, Ness-Ziona, Israel
| | - Sharon Melamed
- Department of Infectious Diseases, Israel Institute for Biological Research, Ness-Ziona, Israel
| | - Boaz Politi
- Department of Infectious Diseases, Israel Institute for Biological Research, Ness-Ziona, Israel
| | - Hagit Achdout
- Department of Infectious Diseases, Israel Institute for Biological Research, Ness-Ziona, Israel
| | - Shmuel Yitzhaki
- Department of Infectious Diseases, Israel Institute for Biological Research, Ness-Ziona, Israel
| | | | - Tamar Sabo
- Department of Biochemistry and Molecular Genetics
| |
Collapse
|
5
|
Elia U, Ramishetti S, Rosenfeld R, Dammes N, Bar-Haim E, Naidu GS, Makdasi E, Yahalom-Ronen Y, Tamir H, Paran N, Cohen O, Peer D. Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered via Lipid Nanoparticles. ACS NANO 2021; 15:9627-9637. [PMID: 33480671 PMCID: PMC7860138 DOI: 10.1021/acsnano.0c10180] [Citation(s) in RCA: 51] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/05/2020] [Accepted: 01/21/2021] [Indexed: 05/20/2023]
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been identified as the causal agent of COVID-19 and stands at the center of the current global human pandemic, with death toll exceeding one million. The urgent need for a vaccine has led to the development of various immunization approaches. mRNA vaccines represent a cell-free, simple, and rapid platform for immunization, and therefore have been employed in recent studies toward the development of a SARS-CoV-2 vaccine. Herein, we present the design of an mRNA vaccine, based on lipid nanoparticles (LNPs)-encapsulated SARS-CoV-2 human Fc-conjugated receptor-binding domain (RBD-hFc). Several ionizable lipids have been evaluated in vivo in a luciferase (luc) mRNA reporter assay, and two leading LNPs formulations have been chosen for the subsequent RBD-hFc mRNA vaccine strategy. Intramuscular administration of LNP RBD-hFc mRNA elicited robust humoral response, a high level of neutralizing antibodies and a Th1-biased cellular response in BALB/c mice. The data in the current study demonstrate the potential of these lipids as promising candidates for LNP-based mRNA vaccines in general and for a COVID19 vaccine in particular.
Collapse
Affiliation(s)
- Uri Elia
- Laboratory of Precision NanoMedicine, Shmunis School
for Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences,
Tel Aviv University, Tel Aviv 69978,
Israel
- Center for Nanoscience and Nanotechnology,
Tel Aviv University, Tel Aviv 69978,
Israel
- Department of Materials Sciences and Engineering, Iby
and Aladar Fleischman Faculty of Engineering, Tel Aviv
University, Tel Aviv 69978, Israel
- Cancer Biology Research Center, Tel Aviv
University, Tel Aviv 69978, Israel
- Department of Biochemistry and Molecular Genetics,
Israel Institute for Biological Research, Ness-Ziona 76100,
Israel
| | - Srinivas Ramishetti
- Laboratory of Precision NanoMedicine, Shmunis School
for Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences,
Tel Aviv University, Tel Aviv 69978,
Israel
- Center for Nanoscience and Nanotechnology,
Tel Aviv University, Tel Aviv 69978,
Israel
- Department of Materials Sciences and Engineering, Iby
and Aladar Fleischman Faculty of Engineering, Tel Aviv
University, Tel Aviv 69978, Israel
- Cancer Biology Research Center, Tel Aviv
University, Tel Aviv 69978, Israel
| | - Ronit Rosenfeld
- Department of Biochemistry and Molecular Genetics,
Israel Institute for Biological Research, Ness-Ziona 76100,
Israel
| | - Niels Dammes
- Laboratory of Precision NanoMedicine, Shmunis School
for Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences,
Tel Aviv University, Tel Aviv 69978,
Israel
- Center for Nanoscience and Nanotechnology,
Tel Aviv University, Tel Aviv 69978,
Israel
- Department of Materials Sciences and Engineering, Iby
and Aladar Fleischman Faculty of Engineering, Tel Aviv
University, Tel Aviv 69978, Israel
- Cancer Biology Research Center, Tel Aviv
University, Tel Aviv 69978, Israel
| | - Erez Bar-Haim
- Department of Biochemistry and Molecular Genetics,
Israel Institute for Biological Research, Ness-Ziona 76100,
Israel
| | - Gonna Somu Naidu
- Laboratory of Precision NanoMedicine, Shmunis School
for Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences,
Tel Aviv University, Tel Aviv 69978,
Israel
- Center for Nanoscience and Nanotechnology,
Tel Aviv University, Tel Aviv 69978,
Israel
- Department of Materials Sciences and Engineering, Iby
and Aladar Fleischman Faculty of Engineering, Tel Aviv
University, Tel Aviv 69978, Israel
- Cancer Biology Research Center, Tel Aviv
University, Tel Aviv 69978, Israel
| | - Efi Makdasi
- Department of Infectious Diseases, Israel
Institute for Biological Research, Ness-Ziona 76100,
Israel
| | - Yfat Yahalom-Ronen
- Department of Infectious Diseases, Israel
Institute for Biological Research, Ness-Ziona 76100,
Israel
| | - Hadas Tamir
- Department of Infectious Diseases, Israel
Institute for Biological Research, Ness-Ziona 76100,
Israel
| | - Nir Paran
- Department of Infectious Diseases, Israel
Institute for Biological Research, Ness-Ziona 76100,
Israel
| | - Ofer Cohen
- Department of Biochemistry and Molecular Genetics,
Israel Institute for Biological Research, Ness-Ziona 76100,
Israel
| | - Dan Peer
- Laboratory of Precision NanoMedicine, Shmunis School
for Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences,
Tel Aviv University, Tel Aviv 69978,
Israel
- Center for Nanoscience and Nanotechnology,
Tel Aviv University, Tel Aviv 69978,
Israel
- Department of Materials Sciences and Engineering, Iby
and Aladar Fleischman Faculty of Engineering, Tel Aviv
University, Tel Aviv 69978, Israel
- Cancer Biology Research Center, Tel Aviv
University, Tel Aviv 69978, Israel
| |
Collapse
|
6
|
Makdasi E, Levy Y, Alcalay R, Noy-Porat T, Zahavy E, Mechaly A, Epstein E, Peretz E, Cohen H, Bar-On L, Chitlaru T, Cohen O, Glinert I, Achdout H, Israely T, Rosenfeld R, Mazor O. Neutralizing Monoclonal Anti-SARS-CoV-2 Antibodies Isolated from Immunized Rabbits Define Novel Vulnerable Spike-Protein Epitope. Viruses 2021; 13:566. [PMID: 33810465 PMCID: PMC8065470 DOI: 10.3390/v13040566] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2021] [Revised: 03/19/2021] [Accepted: 03/24/2021] [Indexed: 12/23/2022] Open
Abstract
Monoclonal antibodies represent an important avenue for COVID-19 therapy and are routinely used for rapid and accessible diagnosis of SARS-CoV-2 infection. The recent emergence of SARS-CoV-2 genetic variants emphasized the need to enlarge the repertoire of antibodies that target diverse epitopes, the combination of which may improve immune-diagnostics, augment the efficiency of the immunotherapy and prevent selection of escape-mutants. Antigen-specific controlled immunization of experimental animals may elicit antibody repertoires that significantly differ from those generated in the context of the immune response mounted in the course of disease. Accordingly, rabbits were immunized by several recombinant antigens representing distinct domains of the viral spike protein and monoclonal antibodies were isolated from single cells obtained by cell sorting. Characterization of a panel of successfully isolated anti-receptor binding domain (RBD) and anti-N-terminal domain (NTD) antibodies demonstrated that they exhibit high specificity and affinity profiles. Anti-RBD antibodies revealing significant neutralizing potency against SARS-CoV-2 in vitro were found to target at least three distinct epitopes. Epitope mapping established that two of these antibodies recognized a novel epitope located on the surface of the RBD. We suggest that the antibodies isolated in this study are useful for designing SARS-CoV-2 diagnosis and therapy approaches.
Collapse
|
7
|
Rosenfeld R, Noy-Porat T, Mechaly A, Makdasi E, Levy Y, Alcalay R, Falach R, Aftalion M, Epstein E, Gur D, Chitlaru T, Vitner EB, Melamed S, Politi B, Zauberman A, Lazar S, Beth-Din A, Evgy Y, Yitzhaki S, Shapira SC, Israely T, Mazor O. Post-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody. Nat Commun 2021; 12:944. [PMID: 33574228 PMCID: PMC7878817 DOI: 10.1038/s41467-021-21239-8] [Citation(s) in RCA: 41] [Impact Index Per Article: 13.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2020] [Accepted: 01/19/2021] [Indexed: 12/11/2022] Open
Abstract
The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), exhibits high levels of mortality and morbidity and has dramatic consequences on human life, sociality and global economy. Neutralizing antibodies constitute a highly promising approach for treating and preventing infection by this novel pathogen. In the present study, we characterize and further evaluate the recently identified human monoclonal MD65 antibody for its ability to provide protection against a lethal SARS-CoV-2 infection of K18-hACE2 transgenic mice. Eighty percent of the untreated mice succumbed 6-9 days post-infection, while administration of the MD65 antibody as late as 3 days after exposure rescued all infected animals. In addition, the efficiency of the treatment is supported by prevention of morbidity and ablation of the load of infective virions in the lungs of treated animals. The data demonstrate the therapeutic value of human monoclonal antibodies as a life-saving treatment for severe COVID-19 infection.
Collapse
MESH Headings
- Animals
- Antibodies, Monoclonal/administration & dosage
- Antibodies, Monoclonal/genetics
- Antibodies, Monoclonal/immunology
- Antibodies, Neutralizing/administration & dosage
- Antibodies, Neutralizing/genetics
- Antibodies, Neutralizing/immunology
- Antibodies, Viral/administration & dosage
- Antibodies, Viral/genetics
- Antibodies, Viral/immunology
- COVID-19/immunology
- Chlorocebus aethiops
- Female
- Immunoglobulin G/administration & dosage
- Immunoglobulin G/genetics
- Immunoglobulin G/immunology
- Lung/pathology
- Lung/virology
- Male
- Mice, Inbred C57BL
- Mice, Transgenic
- SARS-CoV-2/classification
- SARS-CoV-2/physiology
- Seroconversion
- Vero Cells
- Viral Load
- COVID-19 Drug Treatment
- Mice
Collapse
Affiliation(s)
- Ronit Rosenfeld
- Israel Institute for Biological Research, Ness-Ziona, Israel.
| | - Tal Noy-Porat
- Israel Institute for Biological Research, Ness-Ziona, Israel
| | - Adva Mechaly
- Israel Institute for Biological Research, Ness-Ziona, Israel
| | - Efi Makdasi
- Israel Institute for Biological Research, Ness-Ziona, Israel
| | - Yinon Levy
- Israel Institute for Biological Research, Ness-Ziona, Israel
| | - Ron Alcalay
- Israel Institute for Biological Research, Ness-Ziona, Israel
| | - Reut Falach
- Israel Institute for Biological Research, Ness-Ziona, Israel
| | - Moshe Aftalion
- Israel Institute for Biological Research, Ness-Ziona, Israel
| | - Eyal Epstein
- Israel Institute for Biological Research, Ness-Ziona, Israel
| | - David Gur
- Israel Institute for Biological Research, Ness-Ziona, Israel
| | | | - Einat B Vitner
- Israel Institute for Biological Research, Ness-Ziona, Israel
| | - Sharon Melamed
- Israel Institute for Biological Research, Ness-Ziona, Israel
| | - Boaz Politi
- Israel Institute for Biological Research, Ness-Ziona, Israel
| | | | - Shirley Lazar
- Israel Institute for Biological Research, Ness-Ziona, Israel
| | - Adi Beth-Din
- Israel Institute for Biological Research, Ness-Ziona, Israel
| | - Yentl Evgy
- Israel Institute for Biological Research, Ness-Ziona, Israel
| | - Shmuel Yitzhaki
- Israel Institute for Biological Research, Ness-Ziona, Israel
| | | | - Tomer Israely
- Israel Institute for Biological Research, Ness-Ziona, Israel
| | - Ohad Mazor
- Israel Institute for Biological Research, Ness-Ziona, Israel.
| |
Collapse
|
8
|
Choi SK. Nanomaterial-Enabled Sensors and Therapeutic Platforms for Reactive Organophosphates. NANOMATERIALS (BASEL, SWITZERLAND) 2021; 11:224. [PMID: 33467113 PMCID: PMC7830340 DOI: 10.3390/nano11010224] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/20/2020] [Revised: 12/29/2020] [Accepted: 01/14/2021] [Indexed: 01/15/2023]
Abstract
Unintended exposure to harmful reactive organophosphates (OP), which comprise a group of nerve agents and agricultural pesticides, continues to pose a serious threat to human health and ecosystems due to their toxicity and prolonged stability. This underscores an unmet need for developing technologies that will allow sensitive OP detection, rapid decontamination and effective treatment of OP intoxication. Here, this article aims to review the status and prospect of emerging nanotechnologies and multifunctional nanomaterials that have shown considerable potential in advancing detection methods and treatment modalities. It begins with a brief introduction to OP types and their biochemical basis of toxicity followed by nanomaterial applications in two topical areas of primary interest. One topic relates to nanomaterial-based sensors which are applicable for OP detection and quantitative analysis by electrochemical, fluorescent, luminescent and spectrophotometric methods. The other topic is directed on nanotherapeutic platforms developed as OP remedies, which comprise nanocarriers for antidote drug delivery and nanoscavengers for OP inactivation and decontamination. In summary, this article addresses OP-responsive nanomaterials, their design concepts and growing impact on advancing our capability in the development of OP sensors, decontaminants and therapies.
Collapse
Affiliation(s)
- Seok Ki Choi
- Michigan Nanotechnology Institute for Medicine and Biological Sciences, University of Michigan Medical School, Ann Arbor, MI 48109, USA;
- Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109, USA
| |
Collapse
|
9
|
A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. Nat Commun 2020; 11:4303. [PMID: 32855401 PMCID: PMC7452893 DOI: 10.1038/s41467-020-18159-4] [Citation(s) in RCA: 110] [Impact Index Per Article: 27.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2020] [Accepted: 08/05/2020] [Indexed: 12/14/2022] Open
Abstract
The novel highly transmissible human coronavirus SARS-CoV-2 is the causative agent of the COVID-19 pandemic. Thus far, there is no approved therapeutic drug specifically targeting this emerging virus. Here we report the isolation and characterization of a panel of human neutralizing monoclonal antibodies targeting the SARS-CoV-2 receptor binding domain (RBD). These antibodies were selected from a phage display library constructed using peripheral circulatory lymphocytes collected from patients at the acute phase of the disease. These neutralizing antibodies are shown to recognize distinct epitopes on the viral spike RBD. A subset of the antibodies exert their inhibitory activity by abrogating binding of the RBD to the human ACE2 receptor. The human monoclonal antibodies described here represent a promising basis for the design of efficient combined post-exposure therapy for SARS-CoV-2 infection. Here, Noy-Porat, Makdasi et al. report the isolation of a panel of neutralizing mAbs selected against SARS-CoV-2 receptor-binding domain (RBD) from a phage display library constructed based on patient samples collected in the acute phase of the disease, which show efficient neutralizing activities against authentic virus in vitro.
Collapse
|
10
|
Kovarik Z, Maček Hrvat N, Kalisiak J, Katalinić M, Sit RK, Zorbaz T, Radić Z, Fokin VV, Sharpless KB, Taylor P. Counteracting tabun inhibition by reactivation by pyridinium aldoximes that interact with active center gorge mutants of acetylcholinesterase. Toxicol Appl Pharmacol 2019; 372:40-46. [PMID: 30978400 DOI: 10.1016/j.taap.2019.04.007] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2019] [Revised: 04/04/2019] [Accepted: 04/08/2019] [Indexed: 11/28/2022]
Abstract
Tabun represents the phosphoramidate class of organophosphates that are covalent inhibitors of acetylcholinesterase (AChE), an essential enzyme in neurotransmission. Currently used therapy in counteracting excessive cholinergic stimulation consists of a muscarinic antagonist (atropine) and an oxime reactivator of inhibited AChE, but the classical oximes are particularly ineffective in counteracting tabun exposure. In a recent publication (Kovarik et al., 2019), we showed that several oximes prepared by the Huisgen 1,3 dipolar cycloaddition and related precursors efficiently reactivate the tabun-AChE conjugate. Herein, we pursue the antidotal question further and examine a series of lead precursor molecules, along with triazole compounds, as reactivators of two AChE mutant enzymes. Such studies should reveal structural subtleties that reside within the architecture of the active center gorge of AChE and uncover intimate mechanisms of reactivation of alkylphosphate conjugates of AChE. The designated mutations appear to minimize steric constraints of the reactivating oximes within the impacted active center gorge. Indeed, after initial screening of the triazole oxime library and its precursors for the reactivation efficacy on Y337A and Y337A/F338A human AChE mutants, we found potentially active oxime-mutant enzyme pairs capable of degrading tabun in cycles of inhibition and reactivation. Surprisingly, the most sensitive ex vivo reactivation of mutant AChEs occurred with the alkylpyridinium aldoximes. Hence, although the use of mutant enzyme bio-scavengers in humans may be limited in practicality, bioscavenging and efficient neutralization of tabun itself or phosphoramidate mixtures of organophosphates might be achieved efficiently in vitro or ex vivo with these mutant AChE combinations.
Collapse
Affiliation(s)
- Zrinka Kovarik
- Institute for Medical Research and Occupational Health, Zagreb, Croatia.
| | | | - Jarosław Kalisiak
- Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, USA
| | - Maja Katalinić
- Institute for Medical Research and Occupational Health, Zagreb, Croatia
| | - Rakesh K Sit
- Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, USA
| | - Tamara Zorbaz
- Institute for Medical Research and Occupational Health, Zagreb, Croatia
| | - Zoran Radić
- Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California at San Diego, La Jolla, USA
| | - Valery V Fokin
- Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, USA
| | - K Barry Sharpless
- Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, USA
| | - Palmer Taylor
- Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California at San Diego, La Jolla, USA.
| |
Collapse
|
11
|
Liu Q, Peng YJ, Xu JC, Ma C, Li L, Mao CJ, Zhu JJ. Label-Free Electrochemiluminescence Aptasensor for Highly Sensitive Detection of Acetylcholinesterase Based on Au-Nanoparticle-Functionalized g-C3
N4
Nanohybrid. ChemElectroChem 2017. [DOI: 10.1002/celc.201700035] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- Qiao Liu
- School of Chemistry & Chemical Engineering; Anhui University; Hefei 230039 P. R. China
- State Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry & Chemical Engineering; Nanjing University; Nanjing 210093 P. R. China
| | - Yu-Jiao Peng
- State Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry & Chemical Engineering; Nanjing University; Nanjing 210093 P. R. China
| | - Jin-Chun Xu
- State Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry & Chemical Engineering; Nanjing University; Nanjing 210093 P. R. China
| | - Cheng Ma
- State Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry & Chemical Engineering; Nanjing University; Nanjing 210093 P. R. China
| | - Lingling Li
- State Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry & Chemical Engineering; Nanjing University; Nanjing 210093 P. R. China
| | - Chang-Jie Mao
- School of Chemistry & Chemical Engineering; Anhui University; Hefei 230039 P. R. China
| | - Jun-Jie Zhu
- State Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry & Chemical Engineering; Nanjing University; Nanjing 210093 P. R. China
| |
Collapse
|
12
|
Iyengar ARS, Pande AH. Organophosphate-Hydrolyzing Enzymes as First-Line of Defence Against Nerve Agent-Poisoning: Perspectives and the Road Ahead. Protein J 2016; 35:424-439. [DOI: 10.1007/s10930-016-9686-6] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
13
|
Muguruma K, Yakushiji F, Kawamata R, Akiyama D, Arima R, Shirasaka T, Kikkawa Y, Taguchi A, Takayama K, Fukuhara T, Watabe T, Ito Y, Hayashi Y. Novel Hybrid Compound of a Plinabulin Prodrug with an IgG Binding Peptide for Generating a Tumor Selective Noncovalent-Type Antibody-Drug Conjugate. Bioconjug Chem 2016; 27:1606-13. [PMID: 27304609 DOI: 10.1021/acs.bioconjchem.6b00149] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Although several approaches for making antibody-drug conjugates (ADC) have been developed, it has yet to be reported that an antibody binding peptide such as Z33 from protein A is utilized as the pivotal unit to generate the noncovalent-type ADC (NC-ADC). Herein we aim to establish a novel probe for NC-ADC by synthesizing the Z33-conjugated antitumor agent, plinabulin. Due to the different solubility of two components, including hydrophobic plinabulin and hydrophilic Z33, an innovative method with a solid-supported disulfide coupling reagent is required for the synthesis of the target compounds with prominent efficiency (29% isolated yield). We demonstrate that the synthesized hybrid exhibits a binding affinity against the anti-HER2 antibody (Herceptin) and the anti-CD71 antibody (6E1) (Kd = 46.6 ± 0.5 nM and 4.5 ± 0.56 μM, respectively) in the surface plasmon resonance (SPR) assay. In the cell-based assays, the hybrid provides a significant cytotoxicity in the presence of Herceptin against HER2 overexpressing SKBR-3 cells, but not against HER2 low-expressing MCF-7 cells. Further, it is noteworthy that the hybrid in combination with Herceptin induces cytotoxicity against Herceptin-resistant SKBR-3 (SKBR-3HR) cells. Similar results are obtained with the 6E1 antibody, suggesting that the synthesized hybrid can be widely applicable for NC-ADC using the antibody of interest. In summary, a series of evidence presented here strongly indicate that NC-ADCs have high potential for the next generation of antitumor agents.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | - Yuji Ito
- Department of Chemistry and Bioscience, Graduate School of Science and Engineering, Kagoshima University , Korimoto, Kagoshima, 890-0065, Japan
| | | |
Collapse
|
14
|
Zhuang Q, Young A, Callam CS, McElroy CA, Ekici ÖD, Yoder RJ, Hadad CM. Efforts toward treatments against aging of organophosphorus-inhibited acetylcholinesterase. Ann N Y Acad Sci 2016; 1374:94-104. [PMID: 27327269 DOI: 10.1111/nyas.13124] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2016] [Revised: 05/06/2016] [Accepted: 05/10/2016] [Indexed: 11/26/2022]
Abstract
Aging is a dealkylation reaction of organophosphorus (OP)-inhibited acetylcholinesterase (AChE). Despite many studies to date, aged AChE cannot be reactivated directly by traditional pyridinium oximes. This review summarizes strategies that are potentially valuable in the treatment against aging in OP poisoning. Among them, retardation of aging seeks to lower the rate of aging through the use of AChE effectors. These drugs should be administered before AChE is completely aged. For postaging treatment, realkylation of aged AChE by appropriate alkylators may pave the way for oxime treatment by neutralizing the oxyanion at the active site of aged AChE. The other two strategies, upregulation of AChE expression and introduction of exogenous AChE, cannot resurrect aged AChE but may compensate for lowered active AChE levels by in situ production or external introduction of active AChE. Upregulation of AChE expression can be triggered by some peptides. Sources of exogenous AChE can be whole blood or purified AChE, either from human or nonhuman species.
Collapse
Affiliation(s)
- Qinggeng Zhuang
- Department of Chemistry and Biochemistry, The Ohio State University, Columbus, Ohio
| | - Amneh Young
- Department of Chemistry and Biochemistry, The Ohio State University, Columbus, Ohio
| | - Christopher S Callam
- Department of Chemistry and Biochemistry, The Ohio State University, Columbus, Ohio
| | - Craig A McElroy
- College of Pharmacy, The Ohio State University, Columbus, Ohio
| | - Özlem Dogan Ekici
- Department of Chemistry and Biochemistry, The Ohio State University, Columbus, Ohio.,Department of Chemistry and Biochemistry, The Ohio State University-Newark, Newark, Ohio
| | - Ryan J Yoder
- Department of Chemistry and Biochemistry, The Ohio State University, Columbus, Ohio.,Department of Chemistry and Biochemistry, The Ohio State University-Marion, Marion, Ohio
| | - Christopher M Hadad
- Department of Chemistry and Biochemistry, The Ohio State University, Columbus, Ohio
| |
Collapse
|
15
|
Bio-nanocapsule-based scaffold improves the sensitivity and ligand-binding capacity of mammalian receptors on the sensor chip. Biotechnol J 2016; 11:805-13. [DOI: 10.1002/biot.201500443] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2015] [Revised: 03/13/2016] [Accepted: 04/08/2016] [Indexed: 12/19/2022]
|
16
|
Noy-Porat T, Rosenfeld R, Ariel N, Epstein E, Alcalay R, Zvi A, Kronman C, Ordentlich A, Mazor O. Isolation of Anti-Ricin Protective Antibodies Exhibiting High Affinity from Immunized Non-Human Primates. Toxins (Basel) 2016; 8:toxins8030064. [PMID: 26950154 PMCID: PMC4810209 DOI: 10.3390/toxins8030064] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2016] [Revised: 02/25/2016] [Accepted: 02/26/2016] [Indexed: 11/16/2022] Open
Abstract
Ricin, derived from the castor bean plant Ricinus communis, is one of the most potent and lethal toxins known, against which there is no available antidote. To date, the use of neutralizing antibodies is the most promising post-exposure treatment for ricin intoxication. The aim of this study was to isolate high affinity anti-ricin antibodies that possess potent toxin-neutralization capabilities. Two non-human primates were immunized with either a ricin-holotoxin- or subunit-based vaccine, to ensure the elicitation of diverse high affinity antibodies. By using a comprehensive set of primers, immune scFv phage-displayed libraries were constructed and panned. A panel of 10 antibodies (five directed against the A subunit of ricin and five against the B subunit) was isolated and reformatted into a full-length chimeric IgG. All of these antibodies were found to neutralize ricin in vitro, and several conferred full protection to ricin-intoxicated mice when given six hours after exposure. Six antibodies were found to possess exceptionally high affinity toward the toxin, with KD values below pM (koff < 1 × 10−7 s−1) that were well correlated with their ability to neutralize ricin. These antibodies, alone or in combination, could be used for the development of a highly-effective therapeutic preparation for post-exposure treatment of ricin intoxication.
Collapse
Affiliation(s)
- Tal Noy-Porat
- Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 76100, Israel.
| | - Ronit Rosenfeld
- Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 76100, Israel.
| | - Naomi Ariel
- Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 76100, Israel.
| | - Eyal Epstein
- Department of Biotechnology, Israel Institute for Biological Research, Ness-Ziona 76100, Israel.
| | - Ron Alcalay
- Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 76100, Israel.
| | - Anat Zvi
- Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 76100, Israel.
| | - Chanoch Kronman
- Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 76100, Israel.
| | - Arie Ordentlich
- Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 76100, Israel.
| | - Ohad Mazor
- Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 76100, Israel.
| |
Collapse
|